Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dannex Ayrton StarwinXGHA:DASPHARMA 4 Receivables Turnover is 0.00 as of . 20. GuruFocus rates XGHA:DASPHARMA with a GF Score™ of 4/100. The stock has 1 warning sign investors should review. Among 951 Drug Manufacturers companies, Dannex Ayrton Starwin ranks worse than 105152.37% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Dannex Ayrton Starwin's Revenue for the
six
months ended in . 20 was GHS0.00 Mil. Dannex Ayrton Starwin's average Accounts Receivable for the
six
months ended in . 20 was GHS0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Dannex Ayrton Starwin Receivables Turnover Related Terms
Dannex Ayrton Starwin Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Dannex Ayrton Starwin's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dannex Ayrton Starwin Receivables Turnover Chart
Dannex Ayrton Starwin Annual Data
Trend
Receivables Turnover
Dannex Ayrton Starwin Semi-Annual Data
Receivables Turnover
XGHA:DASPHARMA vs : Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dannex Ayrton Starwin's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dannex Ayrton Starwin Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dannex Ayrton Starwin's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Dannex Ayrton Starwin's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a Receivables Turnover of 0.00 as of . 20. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dannex Ayrton Starwin and its competitors. According to the industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 951 companies in the Drug Manufacturers industry.
Is Dannex Ayrton Starwin's Receivables Turnover too high?
Dannex Ayrton Starwin's current Receivables Turnover is 0.00. Based on the distribution chart, Dannex Ayrton Starwin ranks #999999 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dannex Ayrton Starwin has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Dannex Ayrton Starwin's Receivables Turnover compare to ?
According to the Drug Manufacturers industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 951 companies for Receivables Turnover. This places Dannex Ayrton Starwin in the lower half of its industry. The industry median Receivables Turnover is 5.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.06, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dannex Ayrton Starwin and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dannex Ayrton Starwin's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dannex Ayrton Starwin stock overvalued right now?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Dannex Ayrton Starwin's overall GF Score™ is 4/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Dannex Ayrton Starwin (XGHA:DASPHARMA), the current Receivables Turnover is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dannex Ayrton Starwin PLC is a pharmaceutical company. The company offers a product range that includes tablets, capsules, liquids syrups and suspensions, powders, ointments, and chemicals. It also manufactures and distributes Vitamin C.
4GF Score
Get the complete analysis for XGHA:DASPHARMA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:DASPHARMA has been successfully added to your 
